$1.58 Billion is the total value of Consonance Capital Management LP's 26 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | Buy | AMARIN CORP PLCspons adr new | $228,173,000 | +77.4% | 10,990,975 | +16.3% | 14.40% | +52.3% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $143,824,000 | +20.0% | 1,225,387 | +11.3% | 9.08% | +3.0% |
| PCRX | PACIRA PHARMACEUTICALS INC | $139,000,000 | -11.5% | 3,652,134 | 0.0% | 8.77% | -24.1% | |
| QURE | Buy | UNIQURE NV | $118,433,000 | +116.7% | 1,985,460 | +4.7% | 7.48% | +86.0% |
| MYGN | Buy | MYRIAD GENETICS INC | $109,866,000 | +59.4% | 3,309,206 | +39.6% | 6.94% | +36.8% |
| RTRX | RETROPHIN INC | $91,247,000 | 0.0% | 4,032,123 | 0.0% | 5.76% | -14.2% | |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $91,166,000 | +405.0% | 17,875,655 | +90.1% | 5.76% | +333.4% |
| AERI | New | AERIE PHARMACEUTICALS INC | $80,597,000 | – | 1,696,773 | +100.0% | 5.09% | – |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $78,354,000 | -35.6% | 4,258,358 | -8.6% | 4.95% | -44.8% |
| VCEL | Buy | VERICEL CORP | $75,084,000 | +2.3% | 4,288,092 | +1.7% | 4.74% | -12.2% |
| URGN | Buy | UROGEN PHARMA LTD | $64,989,000 | -0.4% | 1,759,324 | +16.1% | 4.10% | -14.5% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $44,949,000 | +36.3% | 2,608,784 | +1.1% | 2.84% | +17.0% |
| CORT | Sell | CORCEPT THERAPEUTICS INC | $43,995,000 | -47.0% | 3,747,453 | -39.7% | 2.78% | -54.5% |
| EPZM | New | EPIZYME INC | $43,096,000 | – | 3,478,261 | +100.0% | 2.72% | – |
| OMER | New | OMEROS CORP | $36,905,000 | – | 2,124,619 | +100.0% | 2.33% | – |
| KDMN | New | KADMON HLDGS INC | $30,698,000 | – | 11,627,900 | +100.0% | 1.94% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $30,128,000 | -33.2% | 5,158,884 | +7.3% | 1.90% | -42.6% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $27,447,000 | +40263.2% | 4,222,558 | +42125.6% | 1.73% | +34560.0% |
| CCXI | New | CHEMOCENTRYX INC | $23,150,000 | – | 1,666,667 | +100.0% | 1.46% | – |
| SVRA | SAVARA INC | $22,800,000 | -2.6% | 3,093,690 | 0.0% | 1.44% | -16.4% | |
| ADMA | ADMA BIOLOGICS INC | $17,390,000 | +58.6% | 4,588,352 | 0.0% | 1.10% | +36.1% | |
| AKBA | New | AKEBIA THERAPEUTICS INC | $11,716,000 | – | 1,430,579 | +100.0% | 0.74% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $10,841,000 | – | 1,140,000 | +100.0% | 0.68% | – |
| ANIP | ANI PHARMACEUTICALS INC | $10,083,000 | +56.7% | 142,943 | 0.0% | 0.64% | +34.5% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $7,503,000 | +8.7% | 9,000,000 | 0.0% | 0.47% | -6.5% | ||
| IMMU | New | IMMUNOMEDICS INC | $2,785,000 | – | 145,000 | +100.0% | 0.18% | – |
| SESN | Exit | SESEN BIO INC | $0 | – | -7,523,296 | -100.0% | -0.79% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -1,155,793 | -100.0% | -0.81% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -2,455,114 | -100.0% | -1.34% | – |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -2,969,027 | -100.0% | -1.91% | – |
| LMNX | Exit | LUMINEX CORP DEL | $0 | – | -2,402,787 | -100.0% | -4.08% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -6,645,113 | -100.0% | -9.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.